You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

~ Buy the PREZCOBIX (cobicistat; darunavir) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR PREZCOBIX

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for PREZCOBIX

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02499978 ↗	Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity	Withdrawn	Janssen Scientific Affairs, LLC	Phase 2/Phase 3	2016-05-01	This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
NCT02499978 ↗	Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity	Withdrawn	University of Colorado, Denver	Phase 2/Phase 3	2016-05-01	This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
NCT02499978 ↗	Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity	Withdrawn	Stanford University	Phase 2/Phase 3	2016-05-01	This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for PREZCOBIX

Condition Name

Chart
Table

Condition Name for PREZCOBIX
Intervention	Trials
HIV/AIDS	1
Healthy	1
Healthy Subjects	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for PREZCOBIX
Intervention	Trials
HIV Infections	1
Acquired Immunodeficiency Syndrome	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for PREZCOBIX

Trials by Country

Map
Table

Trials by Country for PREZCOBIX
Location	Trials
United States	26
Canada	3
Australia	3
Italy	2
Germany	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for PREZCOBIX
Location	Trials
Colorado	2
California	2
Massachusetts	1
Michigan	1
Minnesota	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for PREZCOBIX

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for PREZCOBIX
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2/Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for PREZCOBIX
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PREZCOBIX

Sponsor Name

Chart
Table

Sponsor Name for PREZCOBIX
Sponsor	Trials
Janssen Scientific Affairs, LLC	1
University of Colorado, Denver	1
Stanford University	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for PREZCOBIX
Sponsor	Trials
Industry	5
Other	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.